KKR-Led Consortium Boosts Sylvan Stake to Fund R&D and Asia Capacity Expansion
KKR-led consortium completed an additional investment in Sylvan, retaining majority control and attracting new investors like Novo Holdings. KKR will increase Sylvan’s production capacity, bolster R&D, pursue high-growth product categories and expand its Asia presence via its first Renminbi-denominated fund.
1. KKR CFO to Present at 2026 UBS Financial Services Conference
KKR & Co. Inc. announced that CFO Robert H. Lewin will present at the 2026 UBS Financial Services Conference on February 9, 2026 at 1:00 PM ET. The live webcast will be accessible via the Investor Center on KKR’s website, ensuring global investor participation. A replay will be posted shortly after the presentation, providing on-demand access to insights on KKR’s full-year results, capital deployment strategy and guidance for 2026. Investor Relations will field questions before and after the event, reinforcing KKR’s commitment to transparency and enabling analysts and institutional shareholders to gauge the firm’s outlook across private equity, credit and real assets.
2. KKR-led Consortium Secures Follow-On Investment in Sylvan
KKR today announced the completion of a follow-on investment in Sylvan, a fungal biotechnology leader active in 65 countries. KKR remains the majority investor alongside Novo Holdings, which increased its stake this round, and new backers including TPG NewQuest, PingAn Capital, China Post Insurance, Schroders Capital and Tsao Pao Chee. The transaction was executed through both international and domestic KKR funds, including the firm’s inaugural Renminbi-denominated vehicle. Proceeds will fund expansion of global production capacity, bolster R&D facilities and accelerate entry into high-growth bio-materials markets across Asia. Sylvan CEO Jackie Qi emphasized that this capital injection will support the company’s mission to leverage fungal systems for sustainable solutions in food, agriculture, health and advanced materials.